Biotech group warns of negative impact of Vermont legislation

The US region's largest biotechnology association has warned that a bill under consideration by the state of Vermont Legislature will create the  most restrictive and onerous regulatory environments for the sector's  growth and development, not only in New England, but in the entire  nation. Senate Bill 48, an Act relating to the marketing of prescribed  products, is the focus of a presentation at the State House by Senate  President Peter Shumlin.

"The legislation's radical expansion of Vermont's existing and strict  biopharmaceutical marketing laws promises to hinder significantly the  development of the biotechnology industry in this state," said Paula  Newton, chairperson of the New England Biotech Association.

The NEBA serves as the regional policy and public affairs voice for the  biotechnology and biopharmaceutical community, representing state  associations, companies, academic institutions and other organizations  consisting of more than 800 entities.